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nearly 1 in every 100 pregnant women was prescribed a medi-
cation associated with risk that potentially outweighs possible
beneﬁt according to established pregnancy risk classiﬁcation
systems. The medical care system needs to address this serious
public health problem and focus on the most commonly pre-
scribed drugs associated with fetal harm among pregnant
women because prevention of these exposures may have the
greatest public health impact with respect to drug-related
teratogenicity.
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OBJECTIVE: Little is known about the impact of breast cancer
(BC) and its treatment on health-related work loss among
employed women. This study compared disability in a cohort of
employed women with incident BC to non-cancer controls.
METHODS: The cases were employed women, aged 18–64 with
BC diagnosed between 1999–2005. Control women without
cancer were matched 3:1 on age, comorbidity, and index year.
Cases were selected from an administrative claims database
(MarketScan) using a validated BC case identiﬁcation algorithm.
Short-term disability records were linked to the administrative
claims. Productivity costs were calculated with a Bureau of Labor
Statistics weekly mean wage, matched to subjects by age, sex,
and geography. The durations of employment were described
with separate Kaplan-Meier curves for cases and controls; differ-
ences were tested using the log-rank test. RESULTS: The average
age of the cases (N = 704) and controls (N = 2112) was 48.6
years. Median months of follow-up were 29 for cases and 11 for
controls (p < 0.001). First-year mean (SD) disability days were
60 (70) for cases vs. 5 (19) for controls (p < 0.05). The attribut-
able ﬁrst year disability costs were estimated to be $4900 (95%
CI: $4468, $5322) for cases vs. $385 (95% CI: $319, $449) for
controls (p < 0.001). In years 2 through 4, the number of disabil-
ity days and associated costs were not statistically greater for the
cases versus controls. At 1 year, 11.8% of cases no longer
received employer-sponsored insurance compared to 55.5% of
controls; at 4 years these ﬁgures were 43.6% and 93.5%, respec-
tively (p < 0.001). CONCLUSION: The work loss associated
with BC-related disability is substantial in the ﬁrst year after
diagnosis but the difference between cases and controls is not
sustained in subsequent years. Shorter and longer-term employee
retention is much higher for women with BC compared to those
without cancer.
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OBJECTIVE: To compare clinical and economic outcomes in
women using LNG-IUS one year before and one year after
insertion. METHODS: Adult women (18+) prescribed LNG-
IUS during 2003–2004 were identiﬁed in the MarketScan
claims database (2002–2005). Only women with two years of
continuous eligibility around the devise insertion date (1-year
before and 1-year after insertion) were included. Clinical out-
comes included were menorrhagia or irregular bleeding, dys-
menorrhea, and ﬁbroids-related symptoms. Economic outcomes
included the number of emergency room visits, number of
ofﬁce visits, and health care costs. Both economic and clinical
outcomes were measured and compared between the one year
pre-insertion and one year post-insertion. McNemar’s test was
used to test for signiﬁcant changes in dichotomous variables
and the paired t test was used for continuous variables.
RESULTS: Three thousand nine hundred seventy-nine women
received LNG-IUS. Mean age was 33.6 years (S.D. = 6.7 years).
During one year after the LNG-IUS insertion, women experi-
enced signiﬁcantly less dysmenorrhea (1.5% vs. 2.0%, relative
risk [RR] = 0.74, p = 0.014) and less ﬁbroids-related symptoms
(2.1% vs. 2.4%, RR = 0.86, p = 0.046). No signiﬁcant differ-
ences were found in menorrhagia or irregular bleeding. Emer-
gency room visits also were signiﬁcantly reduced (RR = 0.90,
p < 0.001). Outpatient ofﬁce visits dropped from 12.5 visits
during the pre-insertion year to 10.4 visits during the post-
insertion year (p < 0.001). The total direct health care costs
were $5565 during the year before LNG-IUS use vs. $3141
during the year after, resulting in a $2424 reduction
(p < 0.001). The majority of the cost savings were due to
the cost reduction associated with inpatient hospitaliza-
tions. CONCLUSION: During the ﬁrst year after LNG-IUS
insertion, women experienced signiﬁcant less dysmenorrhea and
ﬁbroids-related symptoms. The use of LNG-IUS was also asso-
ciated with reduction in resource utilization and health care
costs.
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OBJECTIVE: Probiotics are live bacteria or non-pathogenic
yeasts that colonize the gastrointestinal tract, providing health
beneﬁts to the host. Their safety has not been systematically
investigated in pregnancy. Our objective was to review the
evidence for safety of Lactobacillus, Biﬁdobacterium, and Sac-
charomyces during pregnancy. METHODS: Accepted were ran-
domized controlled trials comparing probiotics and placebo
given any time during pregnancy, at any dose, in any form, for
any condition, and given 1 week. Outcomes included birth
weight, gestational age (GA), rates of C-section, malformations
(major/minor), and miscarriage. Two independent reviewers
searched databases (MEDLINE, OLDMEDLINE, CINAHL,
Cochrane Database, DARE, Allied and Complementary Medi-
cine, EMBASE, AltHealthWatch, American Botanical Council,
Natural Database, and Natural Standard) from inception to Sep-
tember 2007, hand-searched their bibliographies, and contacted
experts to identify other trials. Two reviewers extracted data and
assessed study quality using the Downs-Black checklist. Discrep-
ancies (study eligibility, data, quality) were adjudicated through
consensus. Heterogeneity was assessed with chi-squared and
I-squared tests, publication bias with Begg-Mazumdar test.
Random-effects models combined data. RESULTS: Nine studies
examined 1706 patients for three outcomes; none examined birth
defects or miscarriages. Publication bias was not detected
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